AAL

Drug Stock On Track For Best Day Ever After Development Deal

Voyager Therapeutics is the top stock on the Nasdaq this morning

Managing Editor
Jan 29, 2019 at 9:45 AM
facebook X logo linkedin


The shares of Voyager Therapeutics Inc (NASDAQ:VYGR) are up 44% to trade at $11.58 this morning, after the gene therapy specialist inked a development deal with Neurocrine Biosciences (NBIX). The deal will focus on Parkinson's disease and Friedreich's ataxia treatments, and Voyager could get up to $1.7 billion in potential milestone payments on top of the $165 million received up front.

Voyager Therapeutics stock sits at the top of the Nasdaq today, and is on track for its best day ever. VYGR desperately needed this shot in the arm. The stock had carved out a channel of lower lows for the last six months, culminating in a Jan. 24 record bottom of $7.76. Now, the shares have toppled their formerly restrictive 50-day moving average for the first time since an early September bear gap.

Analysts have remained bullish, however. By the numbers, six of the nine in coverage have "strong buy" recommendations on the security. Even more revealing, the average 12-month price target stands all the way up at $24.55.

In the options pits, there has been a distinct preference toward calls -- though it's been amid very low absolute volumes. VYGR has a Schaeffer's put/call open interest ratio (SOIR) of 0.10, in the 2nd percentile of its annual range. In other words, short-term options traders are much more call-skewed than normal.

 

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.